Benzinga | Feb 25, 2021 11:51AM EST

Oppenheimer Maintains Outperform on Sage Therapeutics, Raises Price Target to $102

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:SAGE) with a Outperform and raises the price target from $90 to $102.